Abbott Laboratories Stock

$134.44

0.25%

NYSE, Jul 03, 09:30 pm CET

ISIN

US0028241000

Symbol

ABT

Reports

Quarter | Annual

Index

NYSE Composite, S&P 500

Sector

Health

Industry

Medical specialties

Overview Dividends Analysts Charts News Strategies

Abbott Laboratories Stock price

$134.44

+42.21 45.77% 5Y

NYSE, Closing price Thu, Jul 03 2025

+0.33 0.25%

ISIN

US0028241000

Symbol

ABT

Reports

Quarter | Annual

Index

NYSE Composite, S&P 500

Sector

Health

Industry

Medical specialties

Key metrics

Basic

Market capitalization

$233.9b

Enterprise Value

$240.3b

Net debt

$6.4b

Cash

$6.8b

Shares outstanding

1.7b

Valuation (TTM | estimate)

P/E

17.4 | 25.8

P/S

5.5 | 5.2

EV/Sales

5.7 | 5.3

EV/FCF

36.1

P/B

4.8

Dividends

DPS

$2.24

Yield 1Y | 5Y

1.7% | 1.8%

Growth 1Y | 5Y

7.7% | 11.2%

Payout 1Y | 3Y

29.2% | 42.0%

Increased

11 Years

Financials (TTM | estimate)

Revenue

$42.3b | $45.1b

EBITDA

$9.2b | $12.2b

EBIT

$7.4b | $10.4b

Net Income

$13.5b | $9.1b

Free Cash Flow

$6.7b

Growth (TTM | estimate)

Revenue

5.0% | 7.6%

EBITDA

7.9% | 37.1%

EBIT

12.0%

Net Income

139.8% | -32.3%

Free Cash Flow

35.2%

EPS

$7.7

FCF per Share

$3.8

Short interest

1.2%

Employees

114k

Rev per Employee

$370.0k

As a Free StocksGuide user, you can view scores for all 6,967 stocks worldwide.

Get Started for Free Today

Abbott Laboratories Stock Analysis

Unlock Scores for Free

??

33 Analysts have issued a Abbott Laboratories forecast:

21x Buy

64%

12x Hold

36%

More details on Analyst Estimates Including Price Targets

33 Analysts have issued a Abbott Laboratories forecast:

Buy

64%

Hold

36%

Analyst Estimates with Stock Price Targets

Financial data from Abbott Laboratories

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	42,344 42,344	5% 5% 100%
- Direct Costs	18,589 18,589	3% 3% 44%
Gross Profit	23,755 23,755	7% 7% 56%
- Selling and Administrative Expenses	11,748 11,748	6% 6% 28%
- Research and Development Expense	2,790 2,790	5% 5% 7%
EBITDA	9,217 9,217	8% 8% 22%
- Depreciation and Amortization	1,826 1,826	6% 6% 4%
EBIT (Operating Income) EBIT	7,391 7,391	12% 12% 17%
Net Profit	13,502 13,502	140% 140% 32%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Abbott Laboratories Stock News

Positive

The Motley Fool

●

about 21 hours ago

2 Dividend Stocks to Buy for Decades of Passive Income

In 2013, AbbVie (ABBV -0.93%) became a publicly traded corporation after splitting from its former parent company, Abbott Laboratories (ABT 0.18%). Since then, both have produced strong returns and have been great picks for income-seeking investors, thanks to consistent payout hikes.

Positive

Seeking Alpha

●

7 days ago

Abbott Labs: Proactive, Adaptive, Solid

Abbott's proactive leadership and diversified business model help it navigate macro challenges and market volatility effectively. Strong Q1 performance in Nutrition, Medical Devices, and Vascular segments offsets weakness in Diagnostics and China sales, showcasing resilience and adaptability. Management's focus on gross margin expansion, cost-saving initiatives, and shareholder-friendly policie...

Positive

Seeking Alpha

●

7 days ago

Abbott Laboratories: FreeStyle Libre CGMs And EPD Business Driving Positive Momentum

Key collaborations enable Abbott to increase its global presence and accessibility to patients who haven't used CGMs before, potentially resulting in a 15% CAGR in FreeStyle Libre sales by 2028. With Abbott acquiring rights to 4 more biosimilar products and a double-digit CAGR in the target biosimilar emerging markets, the EPD business could stimulate EPS growth beyond Medical Devices. With an ...

More Abbott Laboratories News

Company Profile

Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, Cardiovascular and Neuromodulation Products, and Other. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Vascular Products segment trades coronary, endovascular, structural heart, vessel closure, and other medical device products. The Other segment comprises of Abbott Medical Optics. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Head office	United States
CEO	Robert Ford
Employees	114,000
Founded	1888
Website	www.abbott.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now